MRGN Advisors provides an exclusive competitive edge in the pharmaceutical sector by leveraging firsthand experience of the environment, anticipate trends and translate them into opportunities for our clients in the fields of Oncology, Cardiovascular, Central Nervous System, Dermatology and Allergology.
Illustrative assignments performed recently:
Definition of a global launch sequence planning for an innovative hemato-oncology product that will create a new market segment.
Focus on identifying, contacting, approaching and negotiating with potential business partners to achieve specific and targeted in-licensing opportunities in the therapeutic areas Cardiovascular, Oncology and/or Internal Medicine.
Preparation of the value story and pitch material based on the assessment of Daiichi Sankyo’s differentiating capabilities, profiling and targeting of life science companies in Europe, USA and Asia, execution of the pitches and initiation of partnering discussions between the parties.
Support the Deloitte consulting team to assist Merck Serono France in a reorganization and increase of the operational effectiveness of the teams and functions involved in the commercialization of hospital care products, especially oncology.
Analysis of the situation at Merck Serono, search for benchmarks and
best practices from other life science companies operating in France with comparable product portfolios.
Forming recommendations to organize end-to-end operations from field activities to digital tools and internal processes, to improve organizational structure and capabilities, and to fine-tune roles and responsibilities along with governance.
Establish iQone Healthcare Group as an emerging international specialty pharmaceutical compan
Analysis of the strengths and weaknesses stemming from the historical corporate activities (Sepropharm and Eqinox)
Preparation of a pitch document to approach potential investors and of a detailed business plan.
Execution of several business development pitches and negotiations to supplement the portfolio, targeting the onco-hematology segment.
Expand the portfolio of specialty care products in the field of rare respiratory diseases and neurodegenerative disorders.
